April 21, 2021 08:05 AM EDT

Covid-19 roundup: BioNTech exec says new production sites could be added to meet demand — report; Giving up on the EC, Valneva looks to individual countries for vaccine supply deals

Nicole DeFeudis

Editor

BioNTech CFO Sierk Poetting says he isn’t ruling out the construction of new production sites to meet demand for its Pfizer-partnered Covid-19 vaccine.

Poetting told …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: BioNTech exec says new production sites could be added to meet demand — report; Giving up on the EC, Valneva looks to individual countries for vaccine supply deals

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Covid-19 roundup: BioN­Tech ex­ec says new pro­duc­tion sites could be added to meet de­mand — re­port; Giv­ing up on the EC, Val­ne­va looks to in­di­vid­ual coun­tries for vac­cine sup­ply deals

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Covid-19 roundup: BioNTech exec says new production sites could be added to meet demand — report; Giving up on the EC, Valneva looks to individual countries for vaccine supply deals

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway